BeOne Medicines SHOCKS World! BRUKINSA’s 71.8% Survival: Cancer Cure NOW?
Did you know a new drug could nearly double the progression-free survival rates for a devastating blood cancer? BeOne Medicines, under its ticker ONC, recently unveiled groundbreaking Phase 3 data for its BTK inhibitor, BRUKINSA, at the European Hematology Association Congress. This innovative medication demonstrated a remarkable 71.8% progression-free survival in patients with chronic lymphocytic leukemia, drastically outperforming older treatments which only achieved 31%. Furthermore, the consistent safety profile observed over almost seven years further solidifies BRUKINSA's position as a foundational treatment. While analysts see significant potential in ONC as an investment, some sources suggest even greater upside might lie in specific AI stocks. Stay informed on the latest breakthroughs and investment opportunities by subscribing to our channel.
Tags/Hashtags: #biopharmaceutical #onc #brukinsa
Leave a Reply